These results suggest that the primary therapeutic benefit of semaglutide in patients with long-standing T1D affected by overweight/obesity is a relatively modest weight loss rather than significant improvements in glucose control and reductions in TDD of insulin. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.